Elisa Sicuri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Elisa Sicuri has a total of 396 co-authors. Here are the top co-authors by number of shared publications:
- Clara Menéndez
ISGlobal
11 shared publications - Pedro Luis Alonso
Global Malaria Programme, World Health Organization, Geneva, Switzerland
7 shared publications - Fabrizio Tediosi
Swiss Tropical and Public Health Institute
6 shared publications - Lesong Conteh
LSE Health, London School of Economics and Political Science, London, UK
6 shared publications - Azucena Bardají
Hospital Clínic – Universitat de Barcelona
5 shared publications Eusebio Macete
Affiliations Centro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique, National Institute of Health, Ministry of Health, Maputo, Mozambique
5 shared publications
Latest Publications
- Open Access
- 10 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Latent transition analysis for longitudinal studies of post-acute infection syndromes
Post-Acute Infectious Syndromes (PAIS) refer to the symptoms persisting months after initial infection. Clinical research studies on this topic often collect rich, multi-modal datasets. Yet, the complexity of the datasets and the lack of a precise clinical case definition pose difficulties in creating comprehensive analyses. Here, we present a generalisable framework for analysing data from longitudinal studies of PAIS using Latent Transition Analysis (LTA). It enables the identification of disease phenotypes and the patient-level analysis of transitions between them, without relying on predefined clinical categorisations. Furthermore, we introduce a method for incorporating covariate information, which enables exploration of how patient characteristics influence disease trajectories. We apply this methodology to the ORCHESTRA dataset, composed of individuals affected by SARS-CoV-2 infection from multiple European centres, for investigation into Post-COVID-19 condition (PCC). 5094 patient assessments were collected at SARS-CoV-2 infection, and at 6, 12, 18, and 24 months of follow-up. Our model identifies distinct PCC phenotypes with patient trajectories impacted by age and sex. Our results highlight how LTA can enhance the interpretability of complex, time-resolved clinical data, support personalized patient monitoring and management, and accelerate therapeutic development for other PAISs, too.
- 10 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessLatent transition analysis for longitudinal studies of post-acute infection syndromes
Post-Acute Infectious Syndromes (PAIS) refer to the symptoms persisting months after initial infection. Clinical research studies on this topic often collect rich, multi-modal datasets. Yet, the complexity of the datasets and the lack of a precise clinical case definition pose difficulties in creating comprehensive analyses. Here, we present a generalisable framework for analysing data from longitudinal studies of PAIS using Latent Transition Analysis (LTA). It enables the identification of disease phenotypes and the patient-level analysis of transitions between them, without relying on predefined clinical categorisations. Furthermore, we introduce a method for incorporating covariate information, which enables exploration of how patient characteristics influence disease trajectories. We apply this methodology to the ORCHESTRA dataset, composed of individuals affected by SARS-CoV-2 infection from multiple European centres, for investigation into Post-COVID-19 condition (PCC). 5094 patient assessments were collected at SARS-CoV-2 infection, and at 6, 12, 18, and 24 months of follow-up. Our model identifies distinct PCC phenotypes with patient trajectories impacted by age and sex. Our results highlight how LTA can enhance the interpretability of complex, time-resolved clinical data, support personalized patient monitoring and management, and accelerate therapeutic development for other PAISs, too.
- Open Access
- 30 December 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 164, 108363
Health-related quality-of-life associated with Chagas disease in Argentina and Spain
- 30 December 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 164, 108363
Open AccessHealth-related quality-of-life associated with Chagas disease in Argentina and Spain
- Open Access
- 18 August 2025
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 54 (5)
Malaria amidst the COVID-19 pandemic in Gabon: an application of autoregressive integrated moving average (ARIMA) models within an interrupted time series (ITS) framework to hospital-based data
Background: Coinciding with the SARS-CoV-2 pandemic, malaria cases and malaria-related deaths increased globally between 2020 and 2022. However, evidence linking the pandemic to increased malaria burden remains ambiguous. We assessed the extent to which an observed malaria resurgence in Lambaréné, Gabon, can be associated with pandemic-related disruptions in malaria control programmes. Methods: Using observational data from two tertiary referral hospitals, spanning 2018 to early 2023, we applied autoregressive integrated moving average (ARIMA) models in an interrupted time series (ITS) framework to test for changes in trends and levels following the onset of the pandemic. The primary outcome is the monthly malaria diagnosis rate (per 1000 all-cause hospital diagnoses). As a sub-analysis, we focused on monthly maternal malaria incidence. Results: Following an initial drop (–47.32, P = 0.031), potentially due to risk-averse behaviours, the malaria diagnosis rate gradually and concavely increased (linear term: 7.32, P = 0.001; squared term: –0.19, P = 0.001) to a peak above pre-pandemic levels. Additional analyses suggest that this resurgence was likely driven by disruptions to malaria control activities and a waning efficacy of malaria control tools administered pre-pandemic. Conversely, a resurgence in maternal malaria incidence was not estimated. Conclusion: Findings align with several national and global descriptive reports, but add a more detailed understanding of underlying dynamics, therefore reinforcing the importance of maintaining malaria control in the general population. The absence of a meaningful increase in maternal malaria provides some reassurance that malaria in pregnancy-specific control remained unchanged during the SARS-CoV-2 pandemic. However, observed peaks in post-pandemic maternal malaria incidence should raise concerns given the risks that malaria poses to this group.
- 18 August 2025
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 54 (5)
Open AccessMalaria amidst the COVID-19 pandemic in Gabon: an application of autoregressive integrated moving average (ARIMA) models within an interrupted time series (ITS) framework to hospital-based data
Background: Coinciding with the SARS-CoV-2 pandemic, malaria cases and malaria-related deaths increased globally between 2020 and 2022. However, evidence linking the pandemic to increased malaria burden remains ambiguous. We assessed the extent to which an observed malaria resurgence in Lambaréné, Gabon, can be associated with pandemic-related disruptions in malaria control programmes. Methods: Using observational data from two tertiary referral hospitals, spanning 2018 to early 2023, we applied autoregressive integrated moving average (ARIMA) models in an interrupted time series (ITS) framework to test for changes in trends and levels following the onset of the pandemic. The primary outcome is the monthly malaria diagnosis rate (per 1000 all-cause hospital diagnoses). As a sub-analysis, we focused on monthly maternal malaria incidence. Results: Following an initial drop (–47.32, P = 0.031), potentially due to risk-averse behaviours, the malaria diagnosis rate gradually and concavely increased (linear term: 7.32, P = 0.001; squared term: –0.19, P = 0.001) to a peak above pre-pandemic levels. Additional analyses suggest that this resurgence was likely driven by disruptions to malaria control activities and a waning efficacy of malaria control tools administered pre-pandemic. Conversely, a resurgence in maternal malaria incidence was not estimated. Conclusion: Findings align with several national and global descriptive reports, but add a more detailed understanding of underlying dynamics, therefore reinforcing the importance of maintaining malaria control in the general population. The absence of a meaningful increase in maternal malaria provides some reassurance that malaria in pregnancy-specific control remained unchanged during the SARS-CoV-2 pandemic. However, observed peaks in post-pandemic maternal malaria incidence should raise concerns given the risks that malaria poses to this group.
- Open Access
Delivering an innovative multi-infection and female genital mutilation screening to high-risk migrant populations (ISMiHealth): study protocol of a cluster randomised controlled trial with embedded process evaluation
Introduction ISMiHealth is a clinical decision support system, integrated as a software tool in the electronic health record system of primary care, that aims to improve the screening performance on infectious diseases and female genital mutilation (FGM) in migrants. The aim of this study is to assess the health impact of the tool and to perform a process evaluation of its feasibility and acceptability when implemented in primary care in Catalonia (Spain). Methods and analysis This study is a cluster randomised control trial where 35 primary care centres in Catalonia, Spain will be allocated into one of the two groups: intervention and control. The health professionals in the intervention centres will receive prompts, through the ISMiHealth software, with screening recommendations for infectious diseases and FGM targeting the migrant population based on an individualised risk assessment. Health professionals of the control centres will follow the current routine practice. A difference in differences analysis of the diagnostic rates for all aggregated infections and each individual condition between the intervention and control centres will be performed. Mixed-effects logistic regression models will be carried out to identify associations between the screening coverage and predictor factors. In addition, a process evaluation will be carried out using mixed methodology. Ethics and dissemination The study protocol has been approved by the institutional review boards at Hospital Clínic (16 June 2022, HCB/2022/0363), Clinical Research Ethics Committee of the Primary Care Research Institute IDIAPJGol (22 June 2022, 22/113-P) and the Almería Research Ethics Committee (27 July 2022, EMC/apg). The study will follow the tenets of the Declaration of Helsinki and Good Clinical Practice. All researchers and associates signed a collaboration agreement in which they undertake to abide by good clinical practice standards. Findings will be disseminated in peer-reviewed journals and communications to congresses. Trial registration number NCT05868005.
Open AccessDelivering an innovative multi-infection and female genital mutilation screening to high-risk migrant populations (ISMiHealth): study protocol of a cluster randomised controlled trial with embedded process evaluation
Introduction ISMiHealth is a clinical decision support system, integrated as a software tool in the electronic health record system of primary care, that aims to improve the screening performance on infectious diseases and female genital mutilation (FGM) in migrants. The aim of this study is to assess the health impact of the tool and to perform a process evaluation of its feasibility and acceptability when implemented in primary care in Catalonia (Spain). Methods and analysis This study is a cluster randomised control trial where 35 primary care centres in Catalonia, Spain will be allocated into one of the two groups: intervention and control. The health professionals in the intervention centres will receive prompts, through the ISMiHealth software, with screening recommendations for infectious diseases and FGM targeting the migrant population based on an individualised risk assessment. Health professionals of the control centres will follow the current routine practice. A difference in differences analysis of the diagnostic rates for all aggregated infections and each individual condition between the intervention and control centres will be performed. Mixed-effects logistic regression models will be carried out to identify associations between the screening coverage and predictor factors. In addition, a process evaluation will be carried out using mixed methodology. Ethics and dissemination The study protocol has been approved by the institutional review boards at Hospital Clínic (16 June 2022, HCB/2022/0363), Clinical Research Ethics Committee of the Primary Care Research Institute IDIAPJGol (22 June 2022, 22/113-P) and the Almería Research Ethics Committee (27 July 2022, EMC/apg). The study will follow the tenets of the Declaration of Helsinki and Good Clinical Practice. All researchers and associates signed a collaboration agreement in which they undertake to abide by good clinical practice standards. Findings will be disseminated in peer-reviewed journals and communications to congresses. Trial registration number NCT05868005.
- Open Access
- 16 May 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (5) , e0002957
Defining a malaria diagnostic pathway from innovation to adoption: Stakeholder perspectives on data and evidence gaps
Malaria, a major global health concern, requires effective diagnostic tools for patient care, disease control, and elimination. The pathway from concept to the adoption of diagnostic products is complex, involving multiple steps and stakeholders. To map this process, our study introduces a malaria-specific diagnostic pathway, synthesising existing frameworks with expert insights. Comprising six major stages and 31 related activities, the pathway retains the core stages from existing frameworks and integrates essential malaria diagnostic activities, such as WHO prequalification processes, global stakeholder involvement, and broader health systems considerations. To understand the scope and availability of evidence guiding the activities along this pathway, we conducted an online survey with 113 participants from various stages of the malaria diagnostic pathway. The survey assessed perceptions on four critical attributes of evidence: clear requirements, alignment with user needs, accuracy and reliability, and public and free availability. It also explored the types of evidence used and the challenges and potential solutions related to evidence generation and use. Respondents reported using a broad range of formal and informal data sources. Findings indicated differing levels of agreement on the attributes across pathway stages, with notable challenges in the Approvals and Manufacturing stage and consistent concerns regarding the public availability of data/evidence. The study offers valuable insights for optimising evidence generation and utilisation across the malaria diagnostic pathway. It highlights the need for enhanced stakeholder collaboration, improved data availability, and increased funding to support effective evidence generation, sharing, and use. We propose actionable solutions, including the use of public data repositories, progressive data sharing policies, open-access publishing, capacity-building initiatives, stakeholder engagement forums, and innovative funding solutions. The developed framework and study insights have broader applications, offering a model adaptable for other diseases, particularly for neglected tropical diseases, which face similar diagnostic challenges.
- 16 May 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (5) , e0002957
Open AccessDefining a malaria diagnostic pathway from innovation to adoption: Stakeholder perspectives on data and evidence gaps
Malaria, a major global health concern, requires effective diagnostic tools for patient care, disease control, and elimination. The pathway from concept to the adoption of diagnostic products is complex, involving multiple steps and stakeholders. To map this process, our study introduces a malaria-specific diagnostic pathway, synthesising existing frameworks with expert insights. Comprising six major stages and 31 related activities, the pathway retains the core stages from existing frameworks and integrates essential malaria diagnostic activities, such as WHO prequalification processes, global stakeholder involvement, and broader health systems considerations. To understand the scope and availability of evidence guiding the activities along this pathway, we conducted an online survey with 113 participants from various stages of the malaria diagnostic pathway. The survey assessed perceptions on four critical attributes of evidence: clear requirements, alignment with user needs, accuracy and reliability, and public and free availability. It also explored the types of evidence used and the challenges and potential solutions related to evidence generation and use. Respondents reported using a broad range of formal and informal data sources. Findings indicated differing levels of agreement on the attributes across pathway stages, with notable challenges in the Approvals and Manufacturing stage and consistent concerns regarding the public availability of data/evidence. The study offers valuable insights for optimising evidence generation and utilisation across the malaria diagnostic pathway. It highlights the need for enhanced stakeholder collaboration, improved data availability, and increased funding to support effective evidence generation, sharing, and use. We propose actionable solutions, including the use of public data repositories, progressive data sharing policies, open-access publishing, capacity-building initiatives, stakeholder engagement forums, and innovative funding solutions. The developed framework and study insights have broader applications, offering a model adaptable for other diseases, particularly for neglected tropical diseases, which face similar diagnostic challenges.
- Open Access
- 17 December 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (Suppl 10) , A6.2-A6
OA-196 Development of a CAA/CCA duplex test for improved diagnosis of human schistosomiasis
Background Schistosomiasis is caused by infection with parasitic worms, schistosomes, and affects hundreds of millions people worldwide. The detection of schistosome circulating cathodic and anodic antigens (CCA and CAA) has proven to be highly valuable in diagnosing intestinal and urinary schistosomiasis. Within the freeBILy project, a CCA/CAA duplex test was developed which detects both antigens simultaneously to improve the diagnostic accuracy and potentially identify Schistosoma spp based on CAA/CCA ratios. Methods CAA and CCA were incorporated into the current laboratory-based UCP-LF test platform utilizing a duplex test-format; i.e. a single prototype device with two parallel lateral flow (LF) strips. Test performance was evaluated using banked sample sets (serum and urine) from two different Schistosoma endemic areas using standardized protocols. Samples were available from both cross-sectional as well as school-age children based population studies. In a subset, CCA/CAA ratios were determined. Results CAA-levels in urine were lower compared to CAA-levels in serum, both for S. mansoni (Sm) and S. haematobium (Sh). Significantly more CCA was observed in Sm urines compared to Sh urines. In urine the CCA/CAA ratio for Sm was significantly higher compared to the CAA/CCA ratio for Sh, while no differences were observed in serum. Species could not be identified unequivocally based on the CCA/CAA ratio. Conclusion Combined detection of CAA and CCA improved diagnostic accuracy and showed added value compared to detection either antigen separately, particularly in Sh settings where the POC-CCA performance is limited. Identification of Schistosoma species based on the CCA/CAA ratio seems challenging due to multiple factors. Generally, CAA and CCA levels in serum and urine show marked differences which would benefit from further focused in-depth studies.
- 17 December 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (Suppl 10) , A6.2-A6
Open AccessOA-196 Development of a CAA/CCA duplex test for improved diagnosis of human schistosomiasis
Background Schistosomiasis is caused by infection with parasitic worms, schistosomes, and affects hundreds of millions people worldwide. The detection of schistosome circulating cathodic and anodic antigens (CCA and CAA) has proven to be highly valuable in diagnosing intestinal and urinary schistosomiasis. Within the freeBILy project, a CCA/CAA duplex test was developed which detects both antigens simultaneously to improve the diagnostic accuracy and potentially identify Schistosoma spp based on CAA/CCA ratios. Methods CAA and CCA were incorporated into the current laboratory-based UCP-LF test platform utilizing a duplex test-format; i.e. a single prototype device with two parallel lateral flow (LF) strips. Test performance was evaluated using banked sample sets (serum and urine) from two different Schistosoma endemic areas using standardized protocols. Samples were available from both cross-sectional as well as school-age children based population studies. In a subset, CCA/CAA ratios were determined. Results CAA-levels in urine were lower compared to CAA-levels in serum, both for S. mansoni (Sm) and S. haematobium (Sh). Significantly more CCA was observed in Sm urines compared to Sh urines. In urine the CCA/CAA ratio for Sm was significantly higher compared to the CAA/CCA ratio for Sh, while no differences were observed in serum. Species could not be identified unequivocally based on the CCA/CAA ratio. Conclusion Combined detection of CAA and CCA improved diagnostic accuracy and showed added value compared to detection either antigen separately, particularly in Sh settings where the POC-CCA performance is limited. Identification of Schistosoma species based on the CCA/CAA ratio seems challenging due to multiple factors. Generally, CAA and CCA levels in serum and urine show marked differences which would benefit from further focused in-depth studies.
- Open Access
Privacy-preserving impact evaluation using Difference-in-Differences
Summary: Difference-in-Differences (DID) is a widely used tool for causal impact evaluation but is constrained by data privacy regulations when applied to sensitive personal information, such as individual-level performance records or healthcare data, that must not be shared with data analysts. Obtaining consent can reduce sample sizes or exclude treated/untreated groups, diminishing statistical power or making estimation impossible. Federated Learning, which shares aggregated statistics to ensure privacy, can address these concerns, but advanced federated DID software packages remain scarce. We derived and developed a federated version of the Callaway and Sant’Anna DID, implemented within the DataSHIELD platform. Our package adheres to DataSHIELD’s security measures and adds extra protections, enhancing data privacy and confidentiality. It reproduces point estimates, asymptotic standard errors, and bootstrapped standard errors equivalent to the non-federated implementation. We demonstrate this functionality on simulated data and real-world data from a malaria intervention in Mozambique. By leveraging federated estimates, we increase effective sample sizes leading to reduced estimation uncertainty, and enable estimation when single data owners cannot share the data but only have access to the treated or untreated group.
Open AccessPrivacy-preserving impact evaluation using Difference-in-Differences
Summary: Difference-in-Differences (DID) is a widely used tool for causal impact evaluation but is constrained by data privacy regulations when applied to sensitive personal information, such as individual-level performance records or healthcare data, that must not be shared with data analysts. Obtaining consent can reduce sample sizes or exclude treated/untreated groups, diminishing statistical power or making estimation impossible. Federated Learning, which shares aggregated statistics to ensure privacy, can address these concerns, but advanced federated DID software packages remain scarce. We derived and developed a federated version of the Callaway and Sant’Anna DID, implemented within the DataSHIELD platform. Our package adheres to DataSHIELD’s security measures and adds extra protections, enhancing data privacy and confidentiality. It reproduces point estimates, asymptotic standard errors, and bootstrapped standard errors equivalent to the non-federated implementation. We demonstrate this functionality on simulated data and real-world data from a malaria intervention in Mozambique. By leveraging federated estimates, we increase effective sample sizes leading to reduced estimation uncertainty, and enable estimation when single data owners cannot share the data but only have access to the treated or untreated group.
- Open Access
- 6 October 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
The contribution of risk perception and social norms to reported preventive behaviour against selected vector-borne diseases in Guyana
Preventing vector-borne diseases (VBDs) mainly relies on effective vector control tools and strategies, which in turn depend on population acceptance and adherence. Inspired by the abundant recent literature on SARS-COV-2, we investigate the relationship between risk perception and preventive behaviour for selected VBDs and the extent to which risk perception is determined by social norms. We use cross-sectional data collected from 497 individuals in four regions of Guyana in 2017. We use a conditional mixed process estimator with multilevel coefficients, estimated through a Generalized Linear Model (GLM) framework, applying a simultaneous equation structure. We find robust results on malaria: risk perception was significantly influenced by the risk perception of the reference group across different definitions of the reference group, hinting at the existence of social norms. Risk perception significantly increased the likelihood of passive behaviour by 4.48%. Less clear-cut results were found for dengue. This study applies quantitative social science methods to public health issues in the context of VBDs. Our findings point to the relevance of tailoring communications on health risks for VBDs to groups defined at the intersection of socio-economic and demographic characteristics. Such tailored strategies are expected to align risk perception among reference groups and boost preventive behaviour.
- 6 October 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Open AccessThe contribution of risk perception and social norms to reported preventive behaviour against selected vector-borne diseases in Guyana
Preventing vector-borne diseases (VBDs) mainly relies on effective vector control tools and strategies, which in turn depend on population acceptance and adherence. Inspired by the abundant recent literature on SARS-COV-2, we investigate the relationship between risk perception and preventive behaviour for selected VBDs and the extent to which risk perception is determined by social norms. We use cross-sectional data collected from 497 individuals in four regions of Guyana in 2017. We use a conditional mixed process estimator with multilevel coefficients, estimated through a Generalized Linear Model (GLM) framework, applying a simultaneous equation structure. We find robust results on malaria: risk perception was significantly influenced by the risk perception of the reference group across different definitions of the reference group, hinting at the existence of social norms. Risk perception significantly increased the likelihood of passive behaviour by 4.48%. Less clear-cut results were found for dengue. This study applies quantitative social science methods to public health issues in the context of VBDs. Our findings point to the relevance of tailoring communications on health risks for VBDs to groups defined at the intersection of socio-economic and demographic characteristics. Such tailored strategies are expected to align risk perception among reference groups and boost preventive behaviour.
- Open Access
- 21 July 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (7) , e010238
Cost-effectiveness of community-based distribution of intermittent preventive treatment of malaria in pregnancy in Madagascar, Mozambique, Nigeria, and the Democratic Republic of Congo
Introduction Malaria in pregnancy is a major driver of maternal and infant mortality in sub-Saharan Africa. The WHO recommends the administration of intermittent preventive treatment with sulfadoxine pyrimethamine (IPTp-SP) at antenatal care (ANC) visits. Despite being a highly cost-effective strategy, IPTp-SP coverage and uptake remains low. A pilot project was conducted to assess the cost-effectiveness (CE) of community-based delivery of IPTp (C-IPTp) in addition to ANC delivery to increase IPTp uptake in the Democratic Republic of Congo (DRC), Madagascar (MDG), Mozambique (MOZ) and Nigeria (NGA). Methods Costs and CE estimates of C-IPTp were calculated according to two scenarios: (1) costs in ‘programmatic mode’ (ie, costs if C-IPTp was to be implemented by national health systems) and (2) costs from the pilot project. The effectiveness of C-IPTp was obtained through estimates of the averted disability-adjusted life-years (DALYs) associated with maternal clinical malaria and anaemia, low birth weight and neonatal mortality. Results Net incremental costs of C-IPTp ranged between US$6138–US$47 177 (DRC), US$5552–US$31 552 (MDG), US$10 202–US$53 221 (MOZ) and US$667–US$28 645 (NGA) per 1000 pregnant women, under scenarios (1) and (2), respectively. Incremental cost-effectiveness ratios (ICERs) ranged between US$15–US$119 in DRC, US$9–US$53 in MDG, US$104–US$543 in MOZ and US$2–US$66 in NGA per DALY averted, under scenarios (1) and (2), respectively. ICERs fall below the WHO recommended CE threshold based on the gross domestic product per capita. Conclusion Findings suggest that C-IPTp is a highly cost-effective intervention. Results can inform policy decisions on adopting and optimising effective interventions for preventing malaria in pregnancy.
- 21 July 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (7) , e010238
Open AccessCost-effectiveness of community-based distribution of intermittent preventive treatment of malaria in pregnancy in Madagascar, Mozambique, Nigeria, and the Democratic Republic of Congo
Introduction Malaria in pregnancy is a major driver of maternal and infant mortality in sub-Saharan Africa. The WHO recommends the administration of intermittent preventive treatment with sulfadoxine pyrimethamine (IPTp-SP) at antenatal care (ANC) visits. Despite being a highly cost-effective strategy, IPTp-SP coverage and uptake remains low. A pilot project was conducted to assess the cost-effectiveness (CE) of community-based delivery of IPTp (C-IPTp) in addition to ANC delivery to increase IPTp uptake in the Democratic Republic of Congo (DRC), Madagascar (MDG), Mozambique (MOZ) and Nigeria (NGA). Methods Costs and CE estimates of C-IPTp were calculated according to two scenarios: (1) costs in ‘programmatic mode’ (ie, costs if C-IPTp was to be implemented by national health systems) and (2) costs from the pilot project. The effectiveness of C-IPTp was obtained through estimates of the averted disability-adjusted life-years (DALYs) associated with maternal clinical malaria and anaemia, low birth weight and neonatal mortality. Results Net incremental costs of C-IPTp ranged between US$6138–US$47 177 (DRC), US$5552–US$31 552 (MDG), US$10 202–US$53 221 (MOZ) and US$667–US$28 645 (NGA) per 1000 pregnant women, under scenarios (1) and (2), respectively. Incremental cost-effectiveness ratios (ICERs) ranged between US$15–US$119 in DRC, US$9–US$53 in MDG, US$104–US$543 in MOZ and US$2–US$66 in NGA per DALY averted, under scenarios (1) and (2), respectively. ICERs fall below the WHO recommended CE threshold based on the gross domestic product per capita. Conclusion Findings suggest that C-IPTp is a highly cost-effective intervention. Results can inform policy decisions on adopting and optimising effective interventions for preventing malaria in pregnancy.
- Open Access
- 21 December 2022
- Published by Elsevier in Gaceta Sanitaria
- Vol. 37, 102275
Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare
- 21 December 2022
- Published by Elsevier in Gaceta Sanitaria
- Vol. 37, 102275
Open AccessDevelopment of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare